Pd32-01 Pre-Clinical Rationale for Combination Pi3k and Brd4 Inhibition in Advanced Prostate Cancer

Journal of Urology - Netherlands
doi 10.1016/j.juro.2016.02.677
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Pd32-09 Combination Effect of Therapies Targeting the Pi3k-Mtor and Ar Signaling Pathways in Prostate Cancer

Journal of Urology
Urology
2016English

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets
Cancer ResearchDrug DiscoveryOncologyPharmacology
2009English

Mp52-01 Combination of Indomethacin and Enzalutamide to Treat Castration-Resistant Prostate Cancer

Journal of Urology
Urology
2018English

Cabozantinib in Combination With Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Combination Hormonal Therapy: A Reassessment Within Advanced Prostate Cancer

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2004English

Dual PI3K-BRD4 Inhibitor SF1126 Inhibits Colorectal Cancer Cell Growth in Vitro and in Vivo

Cellular Physiology and Biochemistry
Physiology
2019English

Heterogeneity of Advanced Prostate Cancer: Clinical Implications of Genomics

Trends in Urology & Men's Health
2017English

Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer

Cancer Letters
Cancer ResearchOncology
2014English

SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy